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  ABSTRACT 
  Objective      There is great interest in the identiﬁ  cation 
of genetic factors that differentiate psoriatic arthritis 
(PsA) from psoriasis vulgaris (PsV), as such discoveries 
could lead to the identiﬁ  cation of distinct underlying 
aetiological pathways. Recent studies identiﬁ  ed single 
nucleotide polymorphisms (SNPs) in the interleukin 
13 (  IL-13  ) gene region as risk factors for PsV. Further 
investigations in one of these studies found the effect 
to be primarily restricted to PsA, thus suggesting the 
discovery of a speciﬁ  c genetic risk factor for PsA. Given 
this intriguing evidence, association to this gene was 
investigated in large collections of PsA and PsV patients 
and healthy controls.   
  Methods      Two SNPs (rs20541 and rs1800925) 
mapping to the  IL-13  gene were genotyped in 1057 
PsA and 778 type I PsV patients using the Sequenom 
genotyping platform. Genotype frequencies were 
compared to those of 5575 healthy controls. Additional 
analyses were performed in phenotypic subgroups 
of PsA (type I or II PsV and in those seronegative for 
rheumatoid factor).   
  Results      Both SNPs were found to be highly associated 
with susceptibility to PsA (rs1800925 ptrend = 
6.1×10  −5   OR 1.33, rs20541 ptrend = 8.0×10  −4   OR 
1.27), but neither SNP was signiﬁ  cantly associated with 
susceptibility to PsV.   
  Conclusions      This study conﬁ  rms that the effect of 
  IL-13   risk locus is speciﬁ  c for PsA, thus highlighting 
a key biological pathway that differentiates PsA from 
PsV. The identiﬁ  cation of markers that differentiate the 
two diseases raises the possibility in future of allowing 
screening of PsV patients to identify those at risk of 
developing  PsA.      
  INTRODUCTION 
  Psoriasis vulgaris (PsV) is a chronic inﬂ  ammatory 
skin disease in which up to 30% of subjects exhibit 
additional inﬂ  ammatory articular disease.    1    This has 
led to psoriatic arthritis (PsA) being recognised as a 
distinct clinical entity. Both conditions are consid-
ered to be complex diseases that are inﬂ  uenced by 
environmental and genetic factors. The genetic lia-
bility towards the susceptibility to PsA, determined 
using the sibling recurrence risk (λ  s  ), is estimated 
to be much higher (λ  s   > 30) than that of PsV (λ  s   = 
8–12).    2       –       4    These differences are suggestive of addi-
tional genetic susceptibility loci for PsA, although 
it is highly likely that environmental factors also 
contribute to these differences.    5    
  A number of genetic risk loci have now been 
identiﬁ  ed that are associated to both diseases; for 
example, variants in the   HLA-Cw6  ,   IL-12B   and 
  IL-23R   regions.    6        7    Interestingly, differences in the 
genetic basis of the two diseases have been iden-
tiﬁ   ed; the association to   HLA-Cw6   appears to 
be stronger for PsV than PsA (OR of 6.9 and 5.0 
respectively).    6    In addition, a German study found 
variants at the   LCE   locus to be associated with 
PsV, but not PsA.    8    However, a subsequent study in 
a British population found single nucleotide poly-
morphisms (SNPs) in this region to be associated 
with PsA.    9    Given the overlap of known genetic risk 
factors, and the observed differences of λ  s  , there 
is great interest in the identiﬁ  cation of risk factors 
that are speciﬁ  c for PsA. Once identiﬁ  ed, if indeed 
they do exist, these speciﬁ  c risk factors could high-
light aetiological pathways that predispose to the 
development of PsA and potentially lead to a bet-
ter understanding of why some patients with PsV 
develop an inﬂ  ammatory arthritis. 
  A number of recent studies investigating the 
genetic susceptibility to PsV identiﬁ  ed association 
to SNPs on chromosome 5q31.    10        11    This region is 
rich in immune-related genes and contains, among 
others, a cluster of four interleukin (  IL  ) genes. There 
is also prior evidence that the region harbours risk 
loci for other common autoimmune or inﬂ  amma-
tory diseases, including Crohn’s disease.    12        13    The 
ﬁ  rst of the PsV studies was a multitiered case–con-
trol study investigating 25 215 gene-centric SNPs, 
which found association to multiple SNPs in, or 
in close proximity to, the   IL-13   gene.    10    This study 
identiﬁ  ed association to three SNPs, rs1800925 (5′ 
upstream), rs20541 (exonic missense, Q144R) and 
rs848 (3′ untranslated region), where carriage of the 
common alleles from any of these SNPs was found 
to increase the risk of PsV. The second study was 
a large genome-wide association study (GWAS) in 
samples of European ancestry, which identiﬁ  ed and 
replicated association to the exonic SNP; rs20541.    11    
A further large GWAS reported only modest asso-
ciation to rs20541 (p = 0.023).    14    All of these stud-
ies contained signiﬁ   cant proportions of patients 
identiﬁ  ed as also having PsA. Further investigation 
of this effect in one of the studies found it to be 
primarily restricted to those individuals with PsA, 
thus suggesting the discovery of a potential speciﬁ  c 
genetic risk factor for PsA.    15    However, no such 
effect was detected in the second study, as associa-
tion was detected to both diseases, and the third 
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California, USA) according to the manufacturers’ speciﬁ  cations 
for the iPLEX chemistry using 10 ng of genomic DNA. Genotype 
cluster plots were evaluated prior to analysis to ensure satisfac-
tory assay performance.   
  Statistical  analysis 
  Data handling, quality control, association and haplotype analy-
ses were performed using the PLINK software package.    21    The 
dataset was ﬁ  ltered to exclude samples and SNPs with a missing 
data rate >10%, in conjunction with 50 other SNPs in the same 
sample collections. Test statistics were calculated for deviation 
from Hardy–Weinberg equilibrium (HWE) using an exact test, 
the Cochran–Armitage trend test, OR (including 95% CI) and 
LD (r    2    and D′). Multiple logistic regression was performed to 
test for independent effects of the two SNPs using Stata (ver-
sion 10.1). The primary PsA analysis consisted of the combined 
analysis of UK and Ireland cases and controls as a single popula-
tion. The PsV analysis compared the UK cases to the UK con-
trols only. In addition, the genotypes of both SNPs were directly 
compared between the two disease groups using the Armitage 
test for trend. 
  Subphenotype analysis was performed within the PsA 
dataset based on, first, the age at onset of psoriasis (type I 
psoriasis has an onset <40 years of age, whereas type II 
psoriasis is defined as an onset >40 years of age) and, sec-
ond, seronegativity for rheumatoid factor in an attempt to 
exclude those patients who may have PsV and coexistent 
rheumatoid arthritis. All subphenotype analyses were per-
formed in UK samples only, where age at onset was available 
for 784 patients and rheumatoid factor status was available 
for 480 patients. Each subphenotype group was compared 
against UK controls and evidence for association was tested 
using the Armitage test for trend. No information was avail-
able regarding the extent of psoriasis or the presence of 
spondyloarthritis. 
  In the interests of exploring whether heterogeneity exists 
between the UK and Ireland PsA datasets and the potential con-
founding it may introduce, data from each population were next 
analysed independently. This was followed by joint analysis 
using an inverse-variance meta-analysis under the assumption 
of ﬁ  xed effects. Allelic heterogeneity between the two groups 
was estimated using the Cochran Q and I    2    statistics.     
  RESULTS 
  Genotyping 
  Both SNPs demonstrated satisfactory clustering of genotypes 
with clear and distinct clusters. Following exclusion of samples 
failing the minimum threshold for missing date, there were 
937 PsA cases, 743 type I PsV cases and 5533 healthy controls 
(5199 UK and 334 Ireland), with a genotyping success rate of 
>99% in the remaining samples.   
study did not attempt a PsA-speciﬁ  c analysis.    11        14    Furthermore, 
there is suggestive evidence from a Chinese study supporting 
the hypothesis that this region is PsA-speciﬁ  c.    16    
  Given this intriguing suggestion of a PsA-speciﬁ  c effect at the 
  IL-13   locus, the association to these SNPs was investigated in 
large sample collections of PsA and PsV patient samples and 
allele and genotype frequencies were compared to a common 
set of healthy controls for which genotype data were already 
available.   
  METHODS 
  Patient  samples 
  Caucasian PsA patients were recruited from three UK rheu-
matology centres and one centre in Ireland, providing a total 
of 1057 genomic DNA samples (885 UK and 172 Ireland), the 
details of which have been described previously.    17       –       19    PsA clas-
siﬁ  cation was deﬁ  ned as the presence of both psoriasis and 
inﬂ  ammatory arthritis, regardless of rheumatoid factor status 
and all had peripheral arthritis. The majority of samples satis-
ﬁ  ed the CASPAR (ClASsiﬁ  action criteria for Psoriatic ARthritis) 
classiﬁ  cation system, although some were collected prior to 
the introduction of this classiﬁ  cation  system.    20    This study 
was approved by the North West Multicentre Research Ethics 
Committee (MREC 99/8/84), and all subjects provided informed 
consent. 
  A total of 778 unrelated patients with type I psoriasis (age of 
disease onset ≤40 years) were recruited from the Dermatology 
Centre, Salford Royal NHS Foundation Trust, The University of 
Manchester, Manchester, UK. All patients gave written informed 
consent and the study was approved by the Salford and Trafford 
Local Research Ethics Committee.   
  SNP  selection 
  Two of the three previously identiﬁ  ed risk SNPs, rs1800925 
and rs20541, were selected for genotyping. The remaining 
SNP, rs848, was not included due to very high linkage disequi-
librium (LD) with rs20541 (D′ = 1.00, r    2    = 0.96 CEU HapMap 
release 22).   
  Control  samples 
  Data for both SNPs were available for healthy controls from 
the Wellcome Trust Case-Control Consortium 2 project (http://
www.wtccc.org.uk). This dataset consists of samples from the 
1958 British Birth Cohort and the UK Blood Service Collection 
genotyped on the Illumina Human1M-Duo. In addition, 375 
control samples were available from Ireland.   
  Genotyping 
  SNP genotyping of the PsA, PsV and Ireland control samples was 
performed using Sequenom’s MassARRAY system (San Diego, 
  Table  1         Summary of genotype and association results for the two SNPs mapping to the  IL-13   gene vicinity for UK/Ireland cases and controls   
 SNP   Genotype 
  Controls (n = 5533)    PsA cases (n = 937) 
 Count/Frq   RAF   HWE   Count/Frq   RAF   ptrend   OR  (CI) 
rs1800925 CC 3715 (67.1)     690 (73.6)     1.33 (1.16 to 1.53)
CT 1619 (29.3) 0.82 0.82 224 (23.9) 0.86 6.1×10  −5 
TT 180 (3.3)     20 (2.1)    
rs20541 GG 3749 (67.8)     679 (72.5)     1.27 (1.10 to 1.45)
GA 1604 (29.0) 0.82 0.82 234 (25.0) 0.86 8.0×10  −4 
  AA 175 (3.2)     18 (1.9)      
      Genotype counts are presented with frequencies in parentheses. 
  HWE, Hardy–Weinberg equilibrium (reported in controls only); RAF, risk allele frequency.     
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Q = 0.22, I    2      =   32.2; rs20541 Q = 0.68, I    2    = 0) (supplementary 
table 1).     
  DISCUSSION 
  The results presented here conﬁ  rm the ﬁ  ndings of Dufﬁ  n   et al  , 
who described association of the   IL-13   locus with PsA, but not 
with PsV. This represents one of the ﬁ  rst replicated examples 
of a differential association between these two closely related 
phenotypes. 
  Although the present results support the observation made by 
Dufﬁ  n   et al   that the effect of rs1800925 is limited to PsA,    15    they 
contradict the ﬁ  ndings reported by Nair   et al     .11    That PsV GWAS 
contained a signiﬁ  cant proportion of PsA cases in the primary 
scan and validation stages, where upon subgroup analysis there 
was signiﬁ  cant association to both PsA and PsV. 
  The discrepancy in ﬁ  ndings could exist for a number of rea-
sons; ﬁ  rst, it could result from a false-negative (type II error) 
in the PsV arm of the present study. However, the study has 
greater than 80% power to detect an effect of similar mag-
nitude to that reported by Nair   et al.   A type II error is there-
fore unlikely, but not impossible. Second, it is conceivable that 
a false-positive (type I error) occurred in the PsV arm of the 
study performed by Nair   et al  . Although this is a well-powered 
study, its samples are drawn from multiple populations (USA, 
Canada, Germany and France) and collections (contributions 
from nine research groups) that may well lead to population 
stratiﬁ  cation and confound results. In support of this possibil-
ity, it is interesting to note that the control allele frequencies 
across the nine individual cohorts genotyped varied from 0.76 
to 0.81 for the rs20541 and rs848 SNPs. Indeed, the paper does 
not report association to rs1890025, the main effect observed 
in this study and that performed by Dufﬁ  n   et al  .    11        15    The effect 
of possible confounding may be further exacerbated by the 
presence of unidentiﬁ  ed PsA cases as most of the PsV patients 
included were not reported as having had a rheumatological 
assessment. However, in spite of these limitations, this remains 
the best powered study to date and, as such, its results should 
not be dismissed casually. On the contrary, the authors should 
  Statistical  analysis 
  Neither SNP demonstrated deviation from HWE in the com-
bined control group. Both SNPs demonstrated similar genotype 
frequencies; however, only moderate LD was observed (r    2    = 
0.23, D′ = 0.49). Signiﬁ  cant association with susceptibility to PsA 
was found for both SNPs (rs1800925 ptrend = 6.1×10  −5  , rs20541 
ptrend = 8.0×10  −4  ), where the major allele increased the risk of 
disease susceptibility (  table 1  ). No signiﬁ  cant association was 
found to type I PsV with either SNP (  table 2  ). Direct comparison 
of the two disease groups demonstrated signiﬁ  cant differences 
for both SNPs (rs1800925 p = 0.015; rs20541 p = 0.004). 
  Association to rs1800925 remained signiﬁ  cant after adjusting 
for rs20541 (p = 0.0065; OR 0.80 (0.69 to 0.94)) in the multiple 
logistic model. However, association to rs20541 did not reach 
signiﬁ  cant statistical signiﬁ  cance on adjustment for rs1800925 
genotypes (p=0.10; OR 0.88 (0.75 to 1.03)). The haplotype 
formed by the two risk alleles (CG) was signiﬁ  cantly enriched 
in cases compared to controls (79.4% vs 74.6%) and is more 
signiﬁ  cantly associated than single-point analysis of either SNP 
(p = 7.55×10  −6  ; OR 1.32) (supplementary table 2). 
  Finally, the association was investigated within phenotypic 
and population-based subgroups within the PsA samples. Both 
SNPs were found to be associated in the type I and seronega-
tive subgroups (  table 3  ). There were no qualitative differences 
between the effect sizes observed in any of the subgroups, 
although the statistical evidence for association was weakened 
due to the smaller sample sizes. 
  Both SNPs remained associated upon independent analysis of 
the UK PsA dataset, with effect sizes similar to those observed in 
the primary analysis, and no signiﬁ  cant deviation from HWE in 
the controls (supplementary table 1). Only rs18900925 was sig-
niﬁ  cantly associated in the Ireland dataset. The failure to detect 
association to rs20541 may well be attributable to decreased 
power due to the small sample numbers in this dataset. Neither 
SNP signiﬁ  cantly deviated from HWE in the Ireland controls. 
Effect estimates for the meta-analysis were consistent with 
those reported for the primary analysis, with no evidence for 
allelic heterogeneity between the two populations (rs1800925 
  Table  2         Summary of genotype and association results for the two SNPs mapping to the   IL-13   gene vicinity for PsV and UK controls samples   
 SNP   Genotype 
  Controls (n = 5199)    PsV cases (n = 743) 
 Count/Frq   RAF   HWE   Count/Frq   RAF   ptrend   OR  (CI) 
rs1800925 CC 3480 (66.9)     511 (68.8)     1.07 (0.92 to 1.24)
CT 1531 (29.4) 0.82 0.96 211 (28.4) 0.83 0.34
TT 169 (3.3)     21 (2.8)    
rs20541 GG 3506 (67.4)     498 (67.0)     0.97 (0.85 to 1.12)
GA 1521 (29.3) 0.82 0.85 217 (29.2) 0.82 0.72
  AA 168 (3.2)     27 (3.6)      
      Genotype counts are presented with frequencies in parentheses. 
  HWE, Hardy–Weinberg equilibrium (reported in controls only); n, number; RAF, risk allele frequency.     
  Table  3         Summary of subphenotype analysis performed in the UK PsA and controls samples   
 SNP   Genotype 
  Type I psoriasis (n = 496)    Type II psoriasis (n = 169)    Seronegative (n = 313) 
 Count/Frq   ptrend   OR  (CI)   Count/Frq   ptrend   OR  (CI)   Count/Frq   ptrend   OR  (CI) 
rs1800925 CC 345 (72.8)   1.28 (1.06 to 1.54) 121 (74.2)   1.37 (1.00 to 1.89) 222 (74.0)   1.33 (1.05 to 1.69)
CT 119 (25.1) 0.0096 39 (23.9) 0.05 71 (23.7) 0.017
TT 10 (2.1)   3 (1.8)   7 (2.3)  
rs20541 GG 347 (73.1)   1.29 (1.07 to 1.56) 116 (7.20)   1.27 (0.93 to 1.74) 221 (74.2)   1.38 (1.09 to 1.76)
GA 119 (25.1) 0.0077 43 (26.7) 0.13 73 (24.5) 0.008
  AA 9 (1.9)     2 (1.2)     4 (1.3)    
      Genotype counts are presented with frequencies in parentheses. 
 n,  number.   
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be commended for organising a consortium with sufﬁ  cient 
power to detect novel susceptibility loci. In light of the con-
tradicting results, further studies in independent sample collec-
tions will be required to validate the differential association of 
the locus with PsA but not PsV. 
  The presence of unclassiﬁ  ed PsA patients within a PsV sam-
ple collection represents a signiﬁ  cant source of confounding for 
studies attempting to identify PsA-speciﬁ  c risk loci. This could 
lead to false-positive associations in PsV samples at PsA speciﬁ  c 
loci and potentially invalidate any attempts to identify such loci. 
Such studies would greatly beneﬁ  t from a PsV sample collection 
screened by a rheumatologist to exclude PsA as a comparator 
group. In the study presented here, the PsV samples were not 
screened by a rheumatologist; however, the lack of association 
with PsV would suggest that only a limited proportion of these 
samples have unclassiﬁ  ed PsA. 
  From the data presented here and in other published studies, 
it is unclear as to which variant is causal or if there are multiple 
independent effects. The present results conﬁ  rm a strong asso-
ciation to rs1800925; however, the results for an independent 
effect at rs20541 are inconclusive. Only rs1800925 remained 
signiﬁ  cant in the multiple logistic model, suggesting that this 
represents the main effect. However, an independent effect at 
rs20541 cannot be ruled out when the effect estimates are taken 
into consideration, indeed the data are suggestive of indepen-
dent effect at this locus. It is likely that a statistically signiﬁ  cant 
association to rs20541 was not achieved in this model due to 
a lack of power. Haplotype analysis found the CG haplotype 
to be more associated than either SNP individually. However, 
the haplotype results should be considered with caution given 
the observed evidence for historical recombination between the 
two SNPs (D′ = 0.49). Larger sample sizes than available for this 
study would be required to robustly conﬁ  rm or rule out any 
potential independent effect for rs20541. 
  The three SNPs implicated to date each have potential func-
tional impact: rs20541 is a missense SNP that maps to exon 4 
of   IL-13   and results in the substitution of a glycine for arginine 
(Q144R), rs1800925 maps to 1 kb of the 5′ of the coding region 
and rs848 is located within the 3′ untranslated region. However, 
it is possible that these SNPs could tag an unknown causal vari-
ant, therefore ﬁ  ne mapping will be required to identify a suit-
able short-list of candidate SNPs to take forward for functional 
evaluation. 
  In conclusion, the present study supports the PsA-speciﬁ  c 
association to SNPs at chromosome 5q31 and potentially high-
lights a key pathway that is distinct for joint inﬂ  ammation in 
psoriatic disease.           
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